Results 61 to 70 of about 6,396 (177)

Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs

Haematologica, 2006
An expert group of the International Committee on Oral Chelators (ICOC) has recommended a universally effective chelation combination protocol of oral deferiprone (L1) during the day (80-110 mg/kg /day) and subcutaneous deferoxamine (40-60 mg/kg) of a ...
GJ Kontoghiorghes, A Kolnagou
doaj  

Design and development of metal-organic framework-based nanocomposite hydrogels for quantification of deferiprone in exhaled breath condensate

BMC Chemistry
In this study, a novel fluorescence nanoprobe based on Materials of Institute Lavoisier (MIL-101) metal-organic frameworks embedding into the agarose hydrogel is fabricated using a hydrothermal technique.
Reza Moharami, Zahra Karimzadeh, Jafar Soleymani, Vahid Jouyban-Gharamaleki, Maryam Khoubnasabjafari, Elaheh Rahimpour, Abolghasem Jouyban   +6 more
doaj   +1 more source

Cell Death in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 9, September 2026.
Regulated cell death pathways, including apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy‐dependent cell death, interact with mitochondrial dysfunction, proteostasis failure, lysosomal stress, glial remodeling, and neuroinflammation across major neurodegenerative diseases.
Tianjiao Li, Qian Zhang, Yichen Wu, Ruixue Huang   +3 more
wiley   +1 more source

ALT elevations correlating with deferiprone chelation.

, 2019
(A) Patient #34, (B) Patient #1, (C) Patient #19 (datafile). Normal ALT
Brenda L. Gallie (249953), Nancy F. Olivieri (6407168), Amir Sabouhanian (6407171)   +2 more
core   +1 more source

Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis. [PDF]

PLoS ONE, 2015
Nephrogenic systemic fibrosis is associated with gadolinium contrast exposure in patients with reduced kidney function and carries high morbidity and mortality.
Chhanda Bose, Judit K Megyesi, Sudhir V Shah, Kim M Hiatt, Kimberly A Hall, Oleg Karaduta, Sundararaman Swaminathan   +6 more
doaj   +1 more source

Ferroptosis: Newly Emerged Regulator for Human Disease

MedComm, Volume 7, Issue 9, September 2026.
Ferroptosis is a key regulated cell death pathway closely involved in cancers, neurodegenerative disorders, acute organ injuries, and cardiovascular and chronic metabolic diseases, representing a promising therapeutic target for diverse human illnesses.
Dandan Xiao, Lin Ye, Tianqi Jiang, Mengyuan Liu, Yuxia Zhou   +4 more
wiley   +1 more source

Incorporation by coordination and release of the iron chelator drug deferiprone from zinc-based metal-organic frameworks

, 2013
A series of new zinc-based metal–organic framework materials has been prepared in which deferiprone is incorporated as a chelating ligand on infinite or tri-zinc secondary building units following deprotonation.
Monika Jurcic (6459635), Spencer, John, Nowell, Harriott, Mark R Warren (16172777), John Spencer (4461472), Jurcic, Monika, Mahon, Mary F., Rebecca A Lane (16172774), Lane, Rebecca A., Michael Paradowski (2209231), Harriot Nowell (16172780), Burrows, Andrew D., Luke L Keenan (16172771), Warren, Mark R., Andrew D Burrows (16039754), Keenan, Luke L., Mary F Mahon (2963811), Paradowski, Michael   +17 more
core   +1 more source

FBS0701 treatment chelates intracellular erythrocytic iron to the same extent as deferiprone but unlike deferiprone, removes iron from erythrocytes.

, 2013
Aliquots 1–5×106 erythrocytes from two separate healthy donors were stained in the dark with 0.125 µM calcein-AM for 15 minutes at 37°C. Cells were washed twice with PBS and allowed to rest for 10 minutes at 37°C in the dark.
Patricia Ferrer (322100), Abhai K. Tripathi (322101), Carla Cerami Hand (322105), Hugh Young Rienhoff Jr (322107), David J. Sullivan Jr (322111), Martha A. Clark (322102)   +5 more
core   +1 more source

Management of Iron Overload in Infants and Toddlers With Diamond–Blackfan Anemia Syndrome: A French–Italian Study

American Journal of Hematology, Volume 101, Issue 8, Page 1856-1865, August 2026.
ABSTRACT Diamond–Blackfan Anemia Syndrome (DBAS) is a rare congenital anemia often requiring chronic red blood cell transfusions from infancy. Without appropriate chelation, iron overload develops early and may be severe; however, no data are available on chelation in patients under 3 years of age.
Francesca Torchio, Baptiste Lecalvez, Emanuela Garelli, Coralie Mallebranche, Adriana Carando, Marie‐Pierre Castex, Nathalie Garnier, Marco Zecca, Nathalie Aladjidi, Elisa Bertoni, Arthur Sterin, Maria Licciardello, Anne Sirvent, Antonella Sau, Isabelle Marie, Benedicte Bruno, Lydie M. Da Costa, Franca Fagioli, Paola Quarello, Thierry Leblanc   +19 more
wiley   +1 more source

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia

American Journal of Hematology, Volume 101, Issue 8, Page 1969-1979, August 2026.
ABSTRACT Exagamglogene autotemcel (exa‐cel) is a one‐time, ex vivo, CRISPR‐Cas9 gene edited cell therapy approved for patients with transfusion dependent β‐thalassemia (TDT) aged 12–35 years. In a Phase 3 study (CLIMB THAL‐111), exa‐cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion ...
Sujit Sheth, Selim Corbacioglu, Josu de la Fuente, Mattia Algeri, Joachim Rupprecht, Kevin H. M. Kuo, Ami J. Shah, Peter Lang, Hayley Merkeley, Ben Carpenter, Markus Y. Mapara, Robert I. Liem, Stephan Grupp, Yogi Chopra, Amanda M. Li, Janet L. Kwiatkowski, Melanie Kirby‐Allen, Maria Domenica Cappellini, Antonis Kattamis, Sakellarios Zairis, Tina Liu, William Hobbs, Haydar Frangoul, Franco Locatelli, Roland Meisel, on behalf of the CLIMB THAL‐111 and CLIMB‐131 Study Groups   +25 more
wiley   +1 more source